spacer
The Healthcare Sales & Marketing Network celebrates 26 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  OSMOPREP 

 HSMN NewsFeed - 17 Jul 2014
Salix and Pharming Announce FDA Approval of RUCONEST(R) for the Treatment of Acute Angioedema Attacks in Patients with Hereditary Angioedema (HAE)
Biopharmaceuticals FDA
 HSMN NewsFeed - 2 Jan 2013
FDA Approves Fulyzaq(TM) (Crofelemer) 125 mg Delayed-Release Tablets for the Symptomatic Relief of Diarrhea in Patients with HIV/AIDS on Anti-Retroviral Therapy (ART)
Biopharmaceuticals FDA HIV/AIDS
 HSMN NewsFeed - 30 Aug 2011
Progenics and Salix Announce FDA Acceptance of sNDA Filing for RELISTOR(R) in Patients with Non-Cancer Pain
Biopharmaceuticals FDA
 HSMN NewsFeed - 8 Jun 2010
Salix Pharmaceuticals Announces NDA Submission For XIFAXAN550 For Treatment of Non-Constipation Irritable Bowel Syndrome
Biopharmaceuticals Gastroenterology FDA
 HSMN NewsFeed - 24 Mar 2010
FDA Approves XIFAXAN(R) 550 MG Tablets for Reduction in Risk of Overt Hepatic Encephalopathy (HE) Recurrence
Biopharmaceuticals FDA
 HSMN NewsFeed - 23 Feb 2010
FDA Advisory Committee Recommends Approval Of XIFAXAN(R) (rifaximin) Tablets, 550 Mg for Maintenance of Remission of Hepatic Encephalopathy
Biopharmaceuticals FDA
 HSMN NewsFeed - 8 Sep 2009
Salix Receives FDA Marketing Approval for METOZOLV ODT (Orally Disintegrating Tablets) for Relief of Diabetic Gastroparesis and Symptomatic Documented GERD
Biopharmaceuticals Gastroenterology FDA
 HSMN NewsFeed - 1 Jun 2009
Positive Results from Salix Pivotal Phase III Study of Rifaximin for the Prevention and Maintenance of Remission of Hepatic Encephalopathy (HE) Presented at Digestive Disease Week (DDW)
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 23 Apr 2009
Salix Presents Highly Statistically Significant Results from the Phase III Pivotal Study of Rifaximin for the Prevention and Maintenance of Remission of Hepatic Encephalopathy (HE)
Biopharmaceuticals
 HSMN NewsFeed - 29 Dec 2008
Salix Receives FDA Complete Response Letter for Balsalazide Tablet
Biopharmaceuticals Gastroenterology FDA
 HSMN NewsFeed - 3 Nov 2008
APRISO(TM) Granted FDA Marketing Approval for Maintenance of Remission of Ulcerative Colitis
Biopharmaceuticals FDA
 HSMN NewsFeed - 6 Oct 2008
Rifaximin Demonstrates Highly Statistically Significant Results in Prevention of Hepatic Encephalopathy in Pivotal Phase 3 Study
Biopharmaceuticals
 HSMN NewsFeed - 6 Feb 2008
Salix Announces Appointment of Mark Sirgo to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 31 Dec 2007
Salix Pharmaceuticals Announces Submission of Granulated Mesalamine New Drug Application
Biopharmaceuticals Gastroenterology FDA
 HSMN NewsFeed - 4 Oct 2007
Salix Announces Statistically Significant Top- Line Results for Second Product Registration Study of Granulated Mesalamine in Ulcerative Colitis
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 4 Oct 2007
Salix Pharmaceuticals Licenses OSMOPREP(TM) To Mayoly-Spindler in France
Biopharmaceuticals Licensing Gastroenterology
 HSMN NewsFeed - 5 Sep 2007
Salix Pharmaceuticals Acquires Patent-Protected Metoclopramide-Zydis(R)
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 5 Sep 2007
Salix Pharmaceuticals Announces Co-Promotion Agreement for Balsalazide
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 5 Sep 2007
Rifaximin Demonstrates Statistically Significant Improvement in Co-Primary Endpoints in Treatment of Diarrhea-Associated Irritable Bowel Syndrome in Phase IIb Study
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 18 Jun 2007
Salix Pharmaceuticals Announces Positive Top Line Results of Balsalazide Tablets Registration Study
Biopharmaceuticals Gastroenterology FDA
 HSMN NewsFeed - 8 Jun 2007
Salix Pharmaceuticals Announces Imminent Launch of Visiclear(R) in Japan
Biopharmaceuticals
 HSMN NewsFeed - 28 Feb 2007
Salix Pharmaceuticals Acquires PEPCID(R) Oral Suspension
Biopharmaceuticals Acquisitions
 HSMN NewsFeed - 20 Dec 2006
Colazal(R) Pediatric Indication Approved
Biopharmaceuticals Gastroenterology FDA
 HSMN NewsFeed - 13 Dec 2006
OSMOPREP(TM) Tablets Granted MHRA Marketing Approval
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 23 Oct 2006
Salix Pharmaceuticals Reports American College of Gastroenterology Update
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 27 Sep 2006
Colazal(R) Food Effect Application Granted FDA Approval
Biopharmaceuticals Gastroenterology FDA
 HSMN NewsFeed - 5 Jul 2006
COLAZAL(R) Pediatric Exclusivity Filing Submitted
Biopharmaceuticals Gastroenterology FDA
Return to NewsFeed  

 Additional items found! 4

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 4 additional stories matching:
OSMOPREP
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.